2 citations
,
February 2023 in “Research Square (Research Square)” The scaffold effectively prevents melanoma relapse and aids wound healing.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
July 2012 in “European journal of cancer” MPA increases cancer spread by boosting Eph A2 activity.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
Lablab purpureus peptides may effectively kill cancer cells with fewer side effects.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
49 citations
,
March 2014 in “Journal of Investigative Dermatology” Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Multiphoton microscopy can effectively assess breast cancer treatment responses without labels.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
2 citations
,
November 2014 in “Pharmaceutical Patent Analyst” Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.
87 citations
,
January 1996 in “Journal of cellular biochemistry” Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
May 2018 in “European Journal of Dermatology” Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
5 citations
,
April 2016 in “PubMed” Cetuximab often causes skin problems, but they can be managed without stopping treatment.
8 citations
,
April 2014 in “Anti-Cancer Drugs” A hormone linked to collagen helps hair grow back in mice after chemotherapy, and may also prevent bone loss.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
11 citations
,
August 2017 in “Supportive care in cancer” Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
January 2024 in “Wiadomości Lekarskie” Exercise-induced particles can slow breast cancer growth by boosting immune response.
21 citations
,
August 1960 in “British journal of dermatology/British journal of dermatology, Supplement” Endoxan often causes hair loss, which usually starts in the third week of treatment.
October 2014 in “Cancer Research” A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.
10 citations
,
October 2009 in “Photomedicine and laser surgery” IPL treatment can significantly reduce hair in faun tail but may need local anesthesia.
February 2026 in “Clinical Cancer Research” The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.